Pharmacotherapy of eating disorders.
Eating disorders are complex, chronic disorders that are difficult to treat. In addition, the 2 primary eating disorders, anorexia nervosa and bulimia nervosa, may have acute, life-threatening consequences. Medication trials for eating disorders have been hampered by high dropout rates, high placebo response, short trial duration, insufficient doses, and difficult outcome measures. Only 1 medication has been FDA approved for any eating disorder to date, and that is for fluoxetine in the treatment of bulimia. Clearly, new large-scale, independent studies using novel agents, and studying the use of medications for both short- and long-term outcomes, are needed.
Jackson
Cherry Wyant
CW
University of Alabama, Birmingham, AL 35294-0018, USA. cwj0002@auburn.edu
Cates
Marshall
M
Lorenz
Raymond
R
D000856:Anorexia Nervosa / Q000188:drug therapy* / Q000523:psychology; D000928:Antidepressive Agents / Q000627:therapeutic use*; D052018:Bulimia Nervosa / Q000188:drug therapy* / Q000523:psychology; D003131:Combined Modality Therapy; D006801:Humans; D044623:Nutrition Therapy; D011379:Prognosis; D016896:Treatment Outcome
D000928:Antidepressive Agents